公开(公告)号：US10308655B2

公开(公告)日：2019-06-04

申请号：US15578086

申请日：2015-12-23

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Sang Dun Choi ,  Prasannavenkatesh Durai ,  Asma Achek

IPC: C07D487/04 ,  A61P1/00 ,  A61P27/02 ,  A61P1/02 ,  A61P7/00 ,  A61P19/06 ,  A61P25/28 ,  A61P11/06 ,  A61P31/12 ,  A61P17/00 ,  A61P19/02 ,  A61P37/08 ,  A61P13/12 ,  A61P27/16 ,  A61P11/00 ,  A61P29/00 ,  A61P1/04 ,  A61P27/00 ,  C07C251/24 ,  C07D207/277 ,  C07D211/26 ,  C07D211/34 ,  C07D243/08 ,  C07D265/30 ,  C07D333/78 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D409/12 ,  C07D471/04 ,  C07D471/10 ,  A61K9/00 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/4178 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/506

Abstract: The present disclosure relates to a novel small molecule TLR2 antagonist, and particularly, to 19 novel TLR2 antagonists, a pharmaceutical composition, including the antagonists, for preventing or treating inflammatory diseases, and a TLR4 regulator.The novel TLR2 antagonists according to the present disclosure can be effectively used as a preparation for oral administration by having low molecular weight and high oral bioavailability, and can be useful in pharmaceutical compositions for preventing or treating inflammatory diseases since the secretion of IL-8 is effectively inhibited and in vivo cytotoxicity is not induced. In addition, the novel TLR2 antagonists according to the present disclosure can be used as a TLR4 regulator.

公开(公告)号：US11186612B2

公开(公告)日：2021-11-30

申请号：US16858071

申请日：2020-04-24

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Moon Suk Kim ,  Sang Dun Choi ,  Seung Hun Park ,  Masaud Shah

IPC: A61K38/08 ,  A61K38/00 ,  A61P17/02 ,  C07K7/06 ,  C07K7/22

Abstract: A substance P analog having a progenitor cell or stem cell recruiting activity and a method of recruiting progenitor cells or stem cells using the substance P analog are disclosed. The substance P analog has an effect of recruiting endogenous progenitor cells or stem cells to a wound or disease-occurring site. Thus, the disclosure also describes its use in recruiting progenitor cells or stem cells and a method of regenerating or treating a damaged organ or tissue, or a method of healing a wound.